HER2-positive - Globe Thesis

Keyword [HER2-positive] Result: 61 - 80 \| Page: 4 of 6
61.	Efficacy And Prognosis Of Trastuzumab With Or After Neoadjuvant Chemotherapy For HER2-positive Breast Cancer
62.	The Mechanism Research On HER2-positive Esophagus Cancer Cell OE19 Resistance To Hsp90 Inhibitor 17-AAG
63.	The Detection And Clinical Significance Of Total CtDNA And HER2 Copy Number During Neoadjuvant Chemotherapy Treatment With Trastuzumab In HER2 Positive Breast Cancer
64.	The Application Of Meta-analysis In The Study Of Tumor Biotherapy
65.	Efficacy And Safety Of Double Target Combined Chemotherapy For HER2 Positive Breast Cancer:A Systematic Review And Meta-analysis
66.	Human/rat HER2-specific Exosome-targeted T Cell Vaccine For HER2~+ Breast Cancer Immunotherapy
67.	Clinical Analysis Of Lapatinib In Combination With Capecitabine Versus Continued Use Of Trastuzumab In Advanced HER2-positive Breast Cancer Patients With Trastuzumab-resistance
68.	Expression And Clinical Significance Of MSI And PD-L1 In HER2-positive Gastric Cancer
69.	PAI-1 Induces Src Inhibitor Resistance Via CCL5 In HER2-positive Breast Cancer Cells
70.	The Relationship Between CRP And D-dimer With The Prognosis Of Advanced HER2 Positive Breast Cancer With Targeted Therapy
71.	Analysis Of Prognostic Factors And Establishment Of Prognostic Model Of Patients With HER2-positive Advanced Breast Cancer
72.	Heterogeneity Of HER2 Positive Breast Cancer
73.	The Suppressive Role Of Inhibitor Of Growth 4(ING4) In HER2-positive Breast Cancer Growth And Metastasis Through PTEN And Its Underlying Mechanism
74.	The Exploratory Study Of Clinical Therapeutic Scheme And Resistance Indexes After TKI Treatment In HER2-positive Advanced Breast Cancer
75.	Design,Expression,functional Verification And Molecular Dynamics Analysis Of Cell-penetrating Peptide Conjugated Antibody
76.	Ginsenoside Rh1 Inhibits The Malignant Biological Behavior Of HER2-positive Breast Cancer Cells Through DDX5
77.	Rational design, characterization and in vivo studies of antibody mimics against HER2
78.	Metabolomic analysis of her2-positive breast cancer cells
79.	Analysis of the oncogenic cooperation between mutp53 and HER2 to propose mutp53 as a biomarker for HER2-positive breast cancer
80.	Anti-tumor Effects And Underlying Mechanisms Of A Bispecific Antibody M802 Targeting HER2/CD3 For HER2-positive Cancers
<<First <Prev Next> Last>> Jump to